Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

被引：0

作者：

Pietanza, M. Catherine ^{[1
]}

Travis, William D. ^{[1
]}

Chan, Timothy A. ^{[1
]}

Ginsberg, Michelle S. ^{[1
]}

Kris, Andrei Holodny Mark G. ^{[1
]}

Krug, Lee M. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

PANCREAS | 2010年 / 39卷 / 02期

关键词：

D O I：

10.1097/01.mpa.0000363940.51906.5a

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：279 / 279

页数：1

共 50 条

[41] A phase II study of S-1 in relapsed small cell lung cancer
Kudo, Keita
Ohyanagi, Fumiyosi
Horiike, Atsushi
Miyauchi, Eisaku
Tahanaka, Hisashi
Yanagitani, Noriko
Saito, Ryouta
Kaburaki, Kyouhei
Sakatani, Toshio
Horai, Takeshi
Nishio, Makoto
MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (02) : 263 - 266
[42] Phase II trial of becatecarin (rebeccamycin analogue) in relapsed sensitive small cell lung cancer (SCLC)
Dowlati, A.
Mekhail, T.
O'Brien, T.
Rutherford, K.
Snell, M.
Ness, A.
Ma, P.
Ivy, S. P.
Halmos, B.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[43] Phase II Trial of Vinflunine in Relapsed Small Cell Lung Cancer
Spigel, David R.
Hainsworth, John D.
Lane, Cassie M.
Clark, Bobby
Burris, Howard A., III
Greco, F. Anthony
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 874 - 878
[44] A phase II trial of bellotecan in relapsed small cell lung cancer
Kim, Y. -C.
Kim, K. -S.
Kim, S. -Y.
Jeong, E. -T.
Jung, M. -H.
Lee, K. -H.
Lee, J. C.
Ryu, J. -S.
Park, K. -O.
Back, S. -M.
Kim, M. -R.
Na, K. -J.
Kim, Y. -H.
Ahn, S. -J.
LUNG CANCER, 2006, 52 : S24 - S24
[45] Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC).
Kim, Y.
Goto, K.
Nishiwaki, Y.
Kubota, K.
Omatsu, H.
Tamura, T.
Ohe, Y.
Kunitoh, H.
Sekine, I.
Yamamoto, N.
Saijo, N.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 386S - 386S
[46] Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
Francesco Gelsomino
Marcello Tiseo
Fausto Barbieri
Ferdinando Riccardi
Luigi Cavanna
Antonio Frassoldati
Angelo Delmonte
Lucia Longo
Claudio Dazzi
Saverio Cinieri
Ida Colantonio
Francesca Sperandi
Giuseppe Lamberti
Stefano Brocchi
Lorenzo Tofani
Luca Boni
Andrea Ardizzoni
British Journal of Cancer, 2021, 125 : 306 - 306
[47] Phase 2 Study of Talazoparib Plus Low-Dose Temozolomide in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
Cummings, A.
Goldman, J.
Mendenhall, M.
Kanamori, D.
Nguyen, A.
Kim, D.
Wainberg, Z.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S815 - S816
[48] A Phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer (SCLC): CALGB 30602
Miller, Antonius A.
Pang, Herbert
Hodgson, Lydia
Ramnath, Nithya
Otterson, Gregory A.
Vokes, Everett E.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S816 - S817
[49] Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer (vol 36, pg 2386, 2018)
Pietanza
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2898 - 2898
[50] Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Farago, Anna F.
Yeap, Beow Y.
Stanzione, Marcello
Hung, Yin P.
Heist, Rebecca S.
Marcoux, J. Paul
Zhong, Jun
Rangachari, Deepa
Barbie, David A.
Phat, Sarah
Myers, David T.
Morris, Robert
Kem, Marina
Dubash, Taronish D.
Kennedy, Elizabeth A.
Digumarthy, Subba R.
Sequist, Lecia V.
Hata, Aaron N.
Maheswaran, Shyamala
Haber, Daniel A.
Lawrence, Michael S.
Shaw, Alice T.
Mino-Kenudson, Mari
Dyson, Nicholas J.
Drapkin, Benjamin J.
CANCER DISCOVERY, 2019, 9 (10) : 1372 - 1387

← 1 2 3 4 5 →